Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients

Multiple Sclerosis and Related Disorders

Volumn 3, Issue 4, 2014, Pages 520-526

  Sangalli, Francesca ^a   Moiola, Lucia ^a   Ferrè, Laura ^a   Radaelli, Marta ^a   Barcella, Valeria ^a   Rodegher, Mariaemma ^a   Colombo, Bruno ^a   Martinelli Boneschi, Filippo ^a   Martinelli, Vittorio ^a   Comi, Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Discontinuation; Multiple sclerosis; Tysabri

Indexed keywords

BETA INTERFERON; CYCLOPHOSPHAMIDE; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB;

ADULT; ARTICLE; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION THERAPY MANAGEMENT; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PROSPECTIVE STUDY; REBOUND; RECURRENCE RISK; RELAPSE;

EID: 84902548597     PISSN: 22110348     EISSN: 22110356     Source Type: Journal    
DOI: 10.1016/j.msard.2014.04.003     Document Type: Article

References (20)

1. G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, and A. Natarajan et al. Risk of natalizumab associated progressive multifocal leukoencephalopathy N Engl J Med 366 20 2012 1870 1880
2. G Borriello, L Prosperini, C Mancinelli, C Gianni, F Fubelli, and C. Pozzilli Pulse monthly steroids during an elective interruption of natalizumab: a post-marketing study Eur J Neurol 19 5 2012 783 787
3. A Chaudhuri, and PO. Behan Natalizumab for relapsing multiple sclerosis N Engl J Med 348 16 2003 1598 1599
4. DB Clifford, A De Luca, DM Simpson, G Arendt, G Giovannoni, and A. Nath Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases Lancet Neurol 9 4 2010 438 446
5. Cohen M, Maillart E, Papeix C, Vukusic S, Brassat D. ENIGM: a French observational study about switching from natalizumab to fingolimod in multiple sclerosis AAN; 2013, S41.002.
6. Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P., et al. Relapse outcomes in fingolimod-treated patients previously exposed to natalizumab: post-hoc analysis from the 4-month, open-label FIRST study. AAN; 2013, P07.103.
7. J Havla, LA Gerdes, I Meinl, M Krumbholz, H Faber, and F. Weber et al. De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate J Neurol 258 9 2011 1665 1669
8. MD Kaufman, R Lee, and HJ. Norton Course of relapsing-remitting multiple sclerosis before, during and after natalizumab Mult Scler 17 4 2011 490 494
9. Kaufman M, Cree B, De Seze J., et al. Effects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study. ENS; 2012, O262.
10. A Kerbrat, E Le Page, E Leray, T Anani, M Coustans, and C. Desormeaux et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients J Neurol Sci 308 1-2 2011 98 102
11. J Killestein, A Vennegoor, EM Strijbis, A Seewann, BW van Oosten, and BM. Uitdehaag et al. Natalizumab drug holiday in multiple sclerosis: poorly tolerated Ann Neurol 68 3 2010 392 395
12. DH Miller, OA Khan, WA Sheremata, LD Blumhardt, GP Rice, and MA. Libonati et al. A controlled trial of natalizumab for relapsing multiple sclerosis N Engl J Med 348 1 2003 15 23
13. PW O'Connor, A Goodman, L Kappos, FD Lublin, DH Miller, and C. Polman et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis Neurology 76 22 2011 1858 1865
14. AB Oturai, N Koch-Henriksen, T Petersen, PE Jensen, F Sellebjerg, and PS. Sorensen Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study Eur J Neurol 16 2009 420 423
15. N Putzki, O Yaldizli, and M. Maurer et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries Eur J Neurol 17 2010 31 37
16. F Rinaldi, D Seppi, M Calabrese, P Perini, and P. Gallo Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings Mult Scler 18 11 2012 1640 1643
17. PS Sorensen, A Bertolotto, G Edan, G Giovannoni, R Gold, and E. Havrdova et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab Mult Scler 18 2 2012 143 152
18. O Stüve, PD Cravens, EM Frohman, JT Phillips, GM Remington, and G. von Geldern et al. Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy Neurology 72 5 2009 396 401
19. O Stüve, CM Marra, KR Jerome, and L. Cook et al. Immune surveillance in Multiple Sclerosis patients treated with natalizumab Ann Neurol 59 2006 743 747
20. MM Vellinga, JA Castelijns, F Barkhof, BM Uitdehaag, and CH. Polman Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients Neurology 70 13 Pt 2 2008 1150 1151